Article in International journal of STD & AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Abdurrahman AbdulhamidDepartment of Statistics, School of Technology, Kano State Polytechnic, Kano, Nigeria.
Bryan E ShepherdDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Usman J WudilVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.
Chelsea Van WykVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.
Faisal S DankishiyaAminu Kano Teaching Hospital, Kano, Nigeria.
Nafiu HussainiDepartment of Mathematical Sciences, Bayero University, Kano, Nigeria.
C William WesterVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.
Muktar H AliyuVanderbilt Institute for Global Health, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-9504-4679
Funding
Optimal Management of HIV Infected Adults at Risk for Kidney Disease in NigeriaU01DK112271 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, WESTER, C. WILLIAM · 2017 to 2022
$3.2M
Etiology of Persistent Microalbuminuria in NigeriaR01DK127912 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALIYU, MUKTAR HASSAN, MUSA, BABA MAIYAKI · 2021 to 2024
$2.2M
Vanderbilt-Nigeria Building Research Capacity in HIV and Non-communicable Diseases (NCDs) (V-BRCH) 2D43TW011544 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Aishatu Adamu, Muktar Hassan Aliyu · 2020 to 2026
$2.1M
Vanderbilt-Nigeria Biostatistics Training Program (VN-BioStat)D43TW012268 · FIC · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Muktar Hassan Aliyu, Nafiu Hussaini · 2022 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Sickle cell trait, APOL1 risk allele status and chronic kidney disease among ART-experienced adults living with HIV in northern Nigeria. · full record | OpenQuestion